

November 24, 2020

To,
**SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED**
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sir,

Sub:- Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements)
Regulation, 2015 – S&P Global Ratings

With reference to the subject mentioned above, kindly find enclosed rating research update issued by S&P Global Ratings for your reference.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

HARISH
VINAYAK KUBER

Digitally signed by
HARISH VINAYAK KUBER
Date: 2020.11.24
19:43:55 +05'30'

Harish Kuber
Company Secretary & Compliance Officer

Encl: S&P Global Ratings

Research Update:

Glenmark Pharmaceuticals 'BB-' Ratings Affirmed, Off CreditWatch On Easing Refinancing Risk; Outlook Stable

November 24, 2020

Rating Action Overview

- India-based Glenmark Pharmaceuticals Ltd.'s syndication of a US\$182.5 million term loan has alleviated its near-term refinancing risk.
- The generics pharmaceutical company's stable operating cash flows and limited capital spending requirements over the next two years will support its deleveraging.
- We are affirming our long-term issuer credit rating on Glenmark and the issue rating on the company's US\$200 million senior unsecured notes at 'BB-'. At the same time, we are removing all the ratings from CreditWatch, where we had placed them with negative implications on July 29, 2020.
- The stable outlook reflects our expectation that Glenmark's operating performance will remain resilient over the next 12-18 months, with its FFO-to-debt ratio sustainably above 20%.

Rating Action Rationale

Glenmark's new term loan will be enough to meet its upcoming debt maturities. Refinancing risks for Glenmark have subsided with the company raising US\$182.5 million in November 2020 via a term loan to redeem a similar amount of its US\$200 million senior unsecured notes due Aug. 2, 2021. While Glenmark intends to refinance the balance amount in the interim, we believe it has sufficient cash (US\$118 million as of Sept. 30, 2020) to repay this amount at maturity in the event it does not refinance.

Glenmark still has access to about US\$100 million under a revolving credit facility at subsidiary Glenmark Holding S.A. until mid-2023. This, together with its available cash, would be sufficient for Glenmark to repay about US\$140 million of outstanding foreign currency convertible bonds (FCCBs) that have a put option on July 28, 2021.

PRIMARY CREDIT ANALYST

Shruti Zatakia
Singapore
+ 65 6216 1094
shruti.zatakia
@spglobal.com

SECONDARY CONTACTS

Neel Gopalakrishnan
Singapore
+ 65-6239-6385
neel.gopalakrishnan
@spglobal.com

Wilfred Tan
Singapore
(65) 6597-6141
wilfred.tan
@spglobal.com

Resilient operating performance supports Glenmark's financial position. After initial disruptions to operations and supply chain due to strict lockdowns imposed across global markets from March through June 2020, the company's revenues should pick up in the rest of the year. We estimate Glenmark's revenues will increase 6%-6.5% in fiscal 2021 (year ending March 31, 2021) and will return to fiscal 2020 growth levels of 8% by fiscal 2022.

India and Europe will drive revenue growth for Glenmark over the next 12-18 months, largely offsetting the effects of continued price erosion of generics in the U.S. markets. These two regions contribute more than 40% of the company's revenues. We estimate revenues from these regions to increase by 8%-10% in fiscal 2021, compared with 15.3% from India and 11.4% from Europe in fiscal 2020. We expect Glenmark's active pharmaceutical ingredients (API) business to also grow by 10% during this period. The company developed the API for Favipiravir and introduced an oral antiviral FabiFlu for the treatment of mild to moderate COVID-19 in India during the year. The company also launched new products in key European markets, tapping on opportunities presented by the pandemic.

We believe Glenmark's continued focus on improving cost efficiencies and lower research and development (R&D) investments augur well for earnings. The company hived off its investment-heavy innovation business into a separate entity under ICHNOS Sciences Inc. in fiscal 2020 and plans to raise fresh capital to fund investment requirements. This should help it maintain R&D investments at 12%-12.5% of revenues in the coming years, lower than the 13%-13.5% in fiscals 2018 and 2019.

Glenmark's cash flows will be sufficient to meet its capital investment requirements. Our expectations of the company's improving leverage is largely based on its stable operating performance rather than meaningful reduction in debt. Glenmark should be able to generate Indian rupee (INR) 9 billion-INR10 billion in operating cash flows during fiscals 2021 and 2022. The company intends to be conservative in capital investments and plans to pay down debt from asset sales proceeds. These factors should help Glenmark reduce its adjusted gross debt to INR48 billion-INR49 billion in fiscal 2021, from INR53 billion in fiscal 2020.

We estimate the company will spend less than INR10 billion annually over the next two years. This compares with more than INR21 billion totally in fiscals 2019 and 2020, primarily owing to the new manufacturing facility in Monroe in the U.S.

In our view, Glenmark will maintain conservative financial policies on shareholder distributions and acquisitions. Despite a wave of consolidation in the generic pharmaceutical space, we expect the company's management to stay away from debt-fueled acquisitions that could stretch its financial ratios beyond our base case.

Outlook

The stable outlook on Glenmark reflects our expectation that the company's operating performance will remain resilient over the next 12-18 months such that its ratio of funds from operations (FFO) to debt stays sustainably above 20%. We also expect Glenmark to maintain sufficient surplus cash and access to credit lines to sustain its adequate liquidity status during this period.

Downside scenario

We may lower the rating if Glenmark's FFO-to-debt ratio falls below 20% on a sustainable basis.

This could happen if:

- The company's margins weaken materially due to slower-than-anticipated revenue growth or high R&D investments; or
- It makes debt-fueled acquisitions or shareholder distributions.

We may also lower the rating if Glenmark's liquidity weakens due to significantly lower cash or access to credit markets.

Upside scenario

We may upgrade Glenmark if the ratio of FFO to debt remains well above 30%. A significant reduction in the company's gross debt supported by improving EBITDA margins and steady working capital and capital spending requirements could result in such deleveraging.

Company Description

Glenmark is an India-based generics pharmaceutical company with presence in the dermatology, respiratory, cardiology, and oncology therapeutic areas. It has 15 manufacturing facilities across four countries, of which nine are approved by the U.S. Food and Drug Administration.

Mr. Glenn Saldanha and family (through trusts) held 46.5% of the company as of March 31, 2020.

Our Base-Case Scenario

Assumptions

- The global pharmaceutical industry will gradually recover in the second half of 2020, from severe pressure experienced in the first half, as hospitals and facilities reopen for elective surgeries. We assume a gradual recovery in 2021 and a full recovery in 2022.
- Glenmark's operating revenues will rise 6%-6.5% in fiscal 2021, with strong recovery in the second half of the fiscal year in line with the pharmaceutical industry. In fiscal 2022, revenues will recover to fiscal 2020 levels of about 8%.
- The company will maintain its focus on cost optimization and reduction in R&D investments, enabling it to keep EBITDA margins at 16%-16.5% in fiscals 2021 and 2022.
- Glenmark will spend 12%-12.5% of its revenues on R&D in fiscals 2021 and 2022, compared with 12.7% in fiscal 2020.
- The company's annual capital expenditure will be INR8.5 billion-INR9 billion in fiscals 2021 and 2022, compared with INR9.3 billion in fiscal 2020.
- It will pay about 10% of its net profits as dividends in fiscals 2021 and 2022.

Key metrics

Based on these assumptions, we arrive at the following key credit metrics:

- FFO-to-debt ratio of 22%-24% in fiscal 2021 and above 25% in fiscal 2022, compared with

18.8% in fiscal 2020.

- EBITDA interest coverage of about 5.5x in fiscals 2021 and 2022, compared with 4.3x in fiscal 2020.

Liquidity

We view Glenmark's liquidity as adequate. We expect the company's liquidity sources to exceed uses by about 1.2x over the 12 months ending Sept. 30, 2021, and net sources to remain positive even if EBITDA declines by 15%. This follows the company's loan syndication program through which it raised US\$182.5 million in November 2020. We believe these funds, along with available revolving credit facilities will be sufficient to redeem the company's senior unsecured notes due August 2021 and the put option on its FCCBs, if exercised.

We expect Glenmark will remain prudent in its risk management. The company has a good track record with banks but limited relationships and credit standing in the capital markets.

We believe Glenmark has a low ability to sustain its liquidity in unlikely but high impact events. The company remains exposed to regulatory risks and restrictions on foreign currency transactions by India's central bank, and this could impact its debt servicing ability.

Principal liquidity sources include:

- Cash and short-term investments of INR8.9 billion and short-term undrawn committed credit lines of US\$100 million as of Sept. 30, 2020.
- Cash from operations that we estimate at about INR11 billion over the 12 months ending Sept. 30, 2021.
- Proceeds from syndicated term loans of US\$182.5 million to be used for meeting the senior notes maturing on Aug. 2, 2021.

Principal liquidity uses include:

- About INR31.7 billion of debt due over the 12 months ending Sept. 30, 2021, including the US\$200 million senior notes maturing on Aug. 2, 2021. We assume the holders of the FCCBs will also exercise the put option on July 28, 2021.
- Maintenance capital spending of INR2 billion during this period.

Issue Ratings - Subordination Risk Analysis

Capital structure

As of March 31, 2020, Glenmark's reported borrowings of INR48.7 billion, consisted of INR35.7 billion (including US\$200 million of senior unsecured notes) in unsecured debt issued by Glenmark and about INR12.9 billion in unsecured debt issued by its subsidiaries.

Analytical conclusions

Glenmark is domiciled in India, and its substantial assets and operations are in India. Therefore, we consider India to be the relevant jurisdiction for our issuance analysis. In our view, the priority

of claims in a theoretical Indian bankruptcy scenario remains highly uncertain for issuances out of India, and as a result we don't distinguish between various levels of subordination. We therefore equalize the issue rating on the senior unsecured notes with our 'BB-' issuer credit rating on Glenmark.

Ratings Score Snapshot

Issuer Credit Rating: BB-/Stable/--

Business risk: Weak

- Country risk: Intermediate
- Industry risk: Low
- Competitive position: Weak

Financial risk: Significant

- Cash flow/Leverage: Significant

Anchor: bb-

Modifiers

- Diversification/Portfolio effect: Neutral (no impact)
- Capital structure: Neutral (no impact)
- Liquidity: Adequate (no impact)
- Financial policy: Neutral (no impact)
- Management and governance: Fair (no impact)
- Comparable rating analysis: Neutral (no impact)

Stand-alone credit profile: bb-

Related Criteria

- General Criteria: Group Rating Methodology, July 1, 2019
- Criteria | Corporates | General: Corporate Methodology: Ratios And Adjustments, April 1, 2019
- Criteria | Corporates | General: Reflecting Subordination Risk In Corporate Issue Ratings, March 28, 2018
- Criteria | Corporates | Recovery: Methodology: Jurisdiction Ranking Assessments, Jan. 20, 2016
- Criteria | Corporates | General: Methodology And Assumptions: Liquidity Descriptors For Global Corporate Issuers, Dec. 16, 2014
- Criteria | Corporates | Industrials: Key Credit Factors For The Pharmaceutical Industry, April 8, 2014
- Criteria | Corporates | General: Corporate Methodology, Nov. 19, 2013
- General Criteria: Country Risk Assessment Methodology And Assumptions, Nov. 19, 2013

- General Criteria: Methodology: Industry Risk, Nov. 19, 2013
- General Criteria: Methodology: Management And Governance Credit Factors For Corporate Entities, Nov. 13, 2012
- General Criteria: Principles Of Credit Ratings, Feb. 16, 2011

Ratings List

Ratings Affirmed; CreditWatch/Outlook Action

	To	From
Glenmark Pharmaceuticals Ltd.		
Issuer Credit Rating	BB-/Stable/--	BB-/Watch Neg/--
Senior Unsecured	BB-	BB-/Watch Neg

Certain terms used in this report, particularly certain adjectives used to express our view on rating relevant factors, have specific meanings ascribed to them in our criteria, and should therefore be read in conjunction with such criteria. Please see Ratings Criteria at www.standardandpoors.com for further information. Complete ratings information is available to subscribers of RatingsDirect at www.capitaliq.com. All ratings affected by this rating action can be found on S&P Global Ratings' public website at www.standardandpoors.com. Use the Ratings search box located in the left column.

Copyright © 2020 by Standard & Poor's Financial Services LLC. All rights reserved.

No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of Standard & Poor's Financial Services LLC or its affiliates (collectively, S&P). The Content shall not be used for any unlawful or unauthorized purposes. S&P and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P's opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P does not act as a fiduciary or an investment advisor except where registered as such. While S&P has obtained information from sources it believes to be reliable, S&P does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives. Rating-related publications may be published for a variety of reasons that are not necessarily dependent on action by rating committees, including, but not limited to, the publication of a periodic update on a credit rating and related analyses.

To the extent that regulatory authorities allow a rating agency to acknowledge in one jurisdiction a rating issued in another jurisdiction for certain regulatory purposes, S&P reserves the right to assign, withdraw or suspend such acknowledgment at any time and in its sole discretion. S&P Parties disclaim any duty whatsoever arising out of the assignment, withdrawal or suspension of an acknowledgment as well as any liability for any damage alleged to have been suffered on account thereof.

S&P keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain business units of S&P may have information that is not available to other S&P business units. S&P has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P reserves the right to disseminate its opinions and analyses. S&P's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.ratingsdirect.com (subscription), and may be distributed through other means, including via S&P publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.

STANDARD & POOR'S, S&P and RATINGSDIRECT are registered trademarks of Standard & Poor's Financial Services LLC.